Tel: 732-484-9848
Fax: 888-484-5008
Email: [email protected]
Building blocks
Bioactive molecules
Product Pathways
All Targets
Antibody-drug conjugate....
Biochemical Reagent
Cell Cycle/DNA Damage
GPCR/G protein
JAK/STAT Signaling
MAPK/ERK Pathway
Membrane Transporter/Io....
Metabolic Enzyme/Protease
Neuronal Signaling
Protein Tyrosine Kinase....
Stem Cells/Wnt
Vitamin D Related
Research Area
Cardiovascular Disease
Metabolic Disease
Neurological Disease
Product Type
All Products
New Products
Featured Products
Home   »   Product Pathways  »  HCV  »  Boceprevir

Products are for research use only. Not for human use. We do not sell to patients.

CS-0361 Boceprevir

(EBP 520;SCH 503034;EBP-520;EBP520;SCH-503034;SCH503034)
Structure Price and Availability of    Boceprevir
United States
Size Price Stock
5mg $80 In-stock Inquiry
10mg $150 In-stock
50mg $250 In-stock
100mg $350 In-stock
200 mg Get quote
500 mg Get quote
 Distributor In Japan:  フナコシ株式会社    電話番号:81-3-5684-1620   
Inquiry for price and availability only. Please place your order via our email or fax.
Contact us for competitive discounts on bulk quantities .
  • Data Sheet
  • Introduction
  • References
  • Related Products

Boceprevir  M.Wt:  519.68
Boceprevir  Formula: C27H45N5O5
Boceprevir  Solubility: 10 mM in DMSO
Boceprevir  Purity: >98%
Boceprevir  Storage:  Please store the product under the recommended conditions in the Certificate of Analysis.
CAS: 394730-60-0

View current batch:

Boceprevir(EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection. IC50 Value: 14 nM (Ki) Target: HCV Boceprevir is a potent inhibitor in both enzyme assay (Ki* = 14 nM) and cell-based replicon assay (EC 90 = 0.35 microM). It is highly selective (2200x) against human neutrophil elastase (HNE). Boceprevir is well tolerated in humans and demonstrated antiviral activity in phase I clinical trials. It is currently in phase II trials. This Account details the complexity and challenges encountered in the drug discovery process. Treatment with Boceprevir triple therapy increased SVR to 63-66% compared to 38% receiving PEG-IFN/RBV therapy. Non-Black patients achieved higher SVR rates compared to Black patients. Responsiveness to interferon in the lead-in phase was predictive for SVR. SVR rates did not differ between patients randomized to RGT with Boceprevir and those treated with a fixed duration. Anaemia was the most important adverse event leading to dose reduction of RBV in 13% of controls and 21% of Boceprevir recipients.

HCV  |   HCV protease  |  
Keywords: buy Boceprevir | Boceprevir Supplier | purchase Boceprevir | Boceprevir cost | Boceprevir manufacturer | order Boceprevir | Boceprevir distributor | Boceprevir structure,chemscene
buy 394730-60-0 | 394730-60-0 Supplier | purchase 394730-60-0 | 394730-60-0 cost | 394730-60-0 manufacturer | order 394730-60-0 | 394730-60-0 distributor | 394730-60-0 structure,chemscene

Tel: 732-484-9848
Fax: 888-484-5008
Email:  [email protected]
Address: 11 Deer Park Drive, Suite 102D Monmouth Junction, NJ 08852.
Products are for research use only. Not for human use. We do not sell to patients. Sitemap | Inhibitor © Copyright 2012. All Rights Reserved.